Stock Update (NASDAQ:SQNM): Sequenom, Inc.

Partners
With The Perinatal Quality Foundation

Sequenom, Inc.
(NASDAQ:SQNM),a life sciences company committed to enabling healthier lives through the
development of innovative products and services, announced today a partnership with the Perinatal
Quality Foundation (PQF) to support an educational program and the creation of a Genetic
Education Module to help health care personnel and their patients better understand and navigate
the prenatal testing process. The mission of the program is to develop a standardized education and
credentialing process for health care personnel providing pre- and post-testing information, and to
provide tools and educational resources to allow each woman to make better informed personal
genetic testing decisions.
The Perinatal Quality Foundation welcomes http://www.capegynaecologist.co.za/ Sequenoms
support of this important nationwide program, said Mary Norton, M.D., President of the Perinatal
Quality Foundation and Professor of Obstetrics, Gynecology and Reproductive Sciences at University
of California, San Francisco. This critical partnership will greatly assist us in achieving our vision of
providing each pregnant woman in the U.S. with access to knowledgeable personnel and educational
resources to enable her to choose the most appropriate prenatal testing decisions for management
of her pregnancy.
The prenatal genetic testing industry has seen significant advancements, including the availability of
cell free DNA (cfDNA) analysis for noninvasive prenatal testing (NIPT), expanded carrier screening

and the introduction of chromosomal microarray analysis (CMA). The Genetic Education Module will
seek to develop and disseminate information to advance the understanding and appropriate clinical
use of these new technologies through the development of objective, evidence-based educational
tools and resources that aim to help a woman make genetic testing decisions that are consistent with
her own preferences and values.
The PQF Genetic Education Module addresses a significant unmet need for unbiased and highquality genetic education among health care providers and patients, said Mary DAlton, M.D., Chair
of The Pregnancy Foundation and Chair of the Department of Obstetrics and Gynecology at
Columbia Presbyterian Medical Center. We are delighted that Sequenom has joined us in support of
this important project.

This PQF program promises to bridge a major

knowledge gap in the rapidly evolving prenatal testing
field. Sequenom is proud to be a sponsor of this
landmark educational initiative, which will support
informed and responsible use of innovative pregnancy
management approaches, such as NIPT, said Daniel
Grosu, M.D., Chief Medical Officer of Sequenom.
PQFs far-reaching educational initiative will include
complementary websites for patients and health care personnel. The websites and accompanying
tools will be designed to provide adequate knowledge and understanding to providers by offering
basic and accurate explanations of genetic tests to most patients, and identify patients who will
benefit from a referral to a genetic counselor or geneticist. The Genetic Educational Module is
expected to launch in early 2016.(Original Source)
Shares of Sequenom closed yesterday at $2.05. SQNM has a 1-year high of $4.80 and a 1-year low of
$1.82. The stocks 50-day moving average is $2.55 and its 200-day moving average is $3.39.
On the ratings front, Sequenom has been the subject of a number of recent research reports. In a
report issued on August 4, Wedbush analyst Zarak Khurshid maintained a Hold rating on SQNM,
with a price target of $3.50, which implies an upside of 70.7% from current levels. Separately, on
May 8, Oppenheimers Ling Wang reiterated a Buy rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the
performance of their past recommendations, Zarak Khurshid and Ling Wang have a total average
return of -3.7% and -9.5% respectively. Khurshid has a success rate of 54.9% and is ranked #3157
out of 3742 analysts, while Wang has a success rate of 28.9% and is ranked #3561.
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides
molecular diagnostic testing services.
http://www.smarteranalyst.com/2015/09/02/stock-update-nasdaqsqnm-sequenom-inc-partners-with-t
he-perinatal-quality-foundation/